Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Matthew P. Zimmerman, Amy Y. Huang, Emily K. Cox, Rose Al Abosy, Wan Lin Chong, Alex Bastian, Katherine J. Vietor, Yacine A. Choutri, Jenna L. Collier, Vasyl Zhabotynsky, Haiyang Wang, Megan E. Fung, Sarah A. Weiss, Emily J. Robitschek, Jia‐Ren Lin, , Brian C. Miller
This study shows CD40 agonist therapy reduces tumor growth in antigen presentation-deficient tumors by reprogramming monocytes and requiring IFN-gamma and CD8+ T cells for efficacy.
bioRxiv · Feb 8, 2026 · PreprintImmunology